CY1107047T1 - Παραγωγα δολαστατινης 15 - Google Patents

Παραγωγα δολαστατινης 15

Info

Publication number
CY1107047T1
CY1107047T1 CY20061100348T CY061100348T CY1107047T1 CY 1107047 T1 CY1107047 T1 CY 1107047T1 CY 20061100348 T CY20061100348 T CY 20061100348T CY 061100348 T CY061100348 T CY 061100348T CY 1107047 T1 CY1107047 T1 CY 1107047T1
Authority
CY
Cyprus
Prior art keywords
mammal
formula
present
amino group
dolastatine
Prior art date
Application number
CY20061100348T
Other languages
Greek (el)
English (en)
Inventor
Bernd Janssen
Teresa Barlozzari
Andreas Haupt
Thomas Zierke
Andreas Kling
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of CY1107047T1 publication Critical patent/CY1107047T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20061100348T 1997-07-18 2006-03-13 Παραγωγα δολαστατινης 15 CY1107047T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives
EP98935531A EP0991658B1 (en) 1997-07-18 1998-07-07 Dolastatin 15 derivatives

Publications (1)

Publication Number Publication Date
CY1107047T1 true CY1107047T1 (el) 2012-09-26

Family

ID=25406130

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100348T CY1107047T1 (el) 1997-07-18 2006-03-13 Παραγωγα δολαστατινης 15

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU2001227375A1 (en) 2000-02-08 2001-08-20 Herbert T. Nagasawa N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7192972B2 (en) * 2002-03-22 2007-03-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
AR079528A1 (es) * 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
WO2015151078A2 (en) 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
AU662551B2 (en) * 1991-08-09 1995-09-07 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
AU3777593A (en) 1992-02-26 1993-09-13 Paul C. Clark System for protecting computers via intelligent tokens or smart cards
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
EP0642530B1 (en) * 1992-05-20 1998-08-12 BASF Aktiengesellschaft Derivatives of dolastatin
PL178766B1 (pl) * 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
US6458765B1 (en) 2002-10-01
PL197884B1 (pl) 2008-05-30
US20100099843A1 (en) 2010-04-22
NO326827B1 (no) 2009-02-23
HRP980397A2 (en) 1999-04-30
PT991658E (pt) 2006-05-31
AR018501A1 (es) 2001-11-28
CA2296036A1 (en) 1999-01-28
CZ2000176A3 (en) 2001-06-13
KR20010021998A (ko) 2001-03-15
TR200000132T2 (tr) 2000-05-22
ZA986358B (en) 2000-01-17
ES2258819T3 (es) 2006-09-01
IL133784A0 (en) 2001-04-30
DK0991658T3 (da) 2006-05-15
BG65212B1 (bg) 2007-07-31
SK286581B6 (sk) 2009-01-07
TW533217B (en) 2003-05-21
JP4508413B2 (ja) 2010-07-21
JP2012211164A (ja) 2012-11-01
US7662786B2 (en) 2010-02-16
CA2296036C (en) 2007-05-01
EP0991658B1 (en) 2005-12-28
US20030153505A1 (en) 2003-08-14
CO4990967A1 (es) 2000-12-26
JP2001515010A (ja) 2001-09-18
CN1268636C (zh) 2006-08-09
HUP0004234A3 (en) 2001-08-28
US6143721A (en) 2000-11-07
CN1264388A (zh) 2000-08-23
BG104089A (en) 2000-12-29
HK1029125A1 (en) 2001-03-23
TR200103545T2 (tr) 2002-06-21
US7084110B2 (en) 2006-08-01
US8163698B2 (en) 2012-04-24
AU750120B2 (en) 2002-07-11
HU228996B1 (hu) 2013-07-29
KR100579748B1 (ko) 2006-05-15
US20060270606A1 (en) 2006-11-30
IL133784A (en) 2005-09-25
NO20000231L (no) 2000-01-17
US20130046077A1 (en) 2013-02-21
EP0991658A1 (en) 2000-04-12
DE69832982D1 (de) 2006-02-02
BR9810911A (pt) 2000-08-01
JP2009137967A (ja) 2009-06-25
CZ303045B6 (cs) 2012-03-07
AU8475898A (en) 1999-02-10
NO20000231D0 (no) 2000-01-17
JP5047935B2 (ja) 2012-10-10
ID24669A (id) 2000-07-27
PL338144A1 (en) 2000-09-25
JP5122429B2 (ja) 2013-01-16
NZ502296A (en) 2002-02-01
MY135057A (en) 2008-01-31
RU2195462C2 (ru) 2002-12-27
SK187999A3 (en) 2000-09-12
DE69832982T2 (de) 2006-08-24
WO1999003879A1 (en) 1999-01-28
HUP0004234A2 (hu) 2001-05-28
ATE314387T1 (de) 2006-01-15
JP2009137968A (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
CY1107047T1 (el) Παραγωγα δολαστατινης 15
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
KR920008065A (ko) 펩타이드 화합물, 그의 제조 방법 및 그를 함유하는 약제학적 조성물
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
IL129238A0 (en) N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds
RU94019334A (ru) Ингибиторы стероид-сульфатазы
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CY1107584T1 (el) Μεθοδοι και συνθεσεις για την προληψη και θepαπεια της αναιμιας
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BG98793A (bg) Нови производни на аминокиселините,методи за тяхното получаване и фармацевтични състави,съдържащи тези съединения
GR3034204T3 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
EA200100983A1 (ru) Производные 13-метилэритромицина
NZ326238A (en) Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
IS5588A (is) Æxliseyðandi miðlar
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
NO20031671L (no) Dioksolananaloger for forbedret intercellulaer avlevering
EP0830456A4 (en) INSULATED FrpB NUCLEIC ACID MOLECULE AND CORRESPONDING VACCINE
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
DE69330601D1 (de) Serotoninergische ergolin derivate
BG99889A (bg) Инхибитори на рибонуклеотидната редуктаза на херпесния вирус
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
RU95102147A (ru) Производные 1-[2-(1н-инден-3-ил)этил]-4-(нафт-1-ил)пиперазина, способ их получения и содержащие их медикамент и фармацевтический состав
GB2316406A (en) Free radical scavenger molecules